OXFYY (Oxford Nanopore Technologies) ROE % Adjusted to Book Value : -13.38% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Oxford Nanopore Technologies ROE % Adjusted to Book Value?

Oxford Nanopore Technologies's ROE % for the quarter that ended in Jun. 2024 was -24.49%. Oxford Nanopore Technologies's PB Ratio for the quarter that ended in Jun. 2024 was 1.83. Oxford Nanopore Technologies's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -13.38%.

Oxford Nanopore Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Oxford Nanopore Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Nanopore Technologies ROE % Adjusted to Book Value Chart

Oxford Nanopore Technologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Oxford Nanopore Technologies Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	-	-	-	-13.38

Competitive Comparison of Oxford Nanopore Technologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oxford Nanopore Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford Nanopore Technologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oxford Nanopore Technologies's ROE % Adjusted to Book Value falls into.

Oxford Nanopore Technologies ROE % Adjusted to Book Value Calculation

Oxford Nanopore Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-23.57%	/	N/A
	=	N/A

Oxford Nanopore Technologies's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-24.49%	/	1.83
	=	-13.38%

Oxford Nanopore Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oxford Nanopore Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Nanopore Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Nanopore Technologies PLC (OTCPK:OXFYY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ONTTF:USA ONTl:UK ONT:UK 4R0:Germany

Address

Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, GBR, OX4 4DQ

Website

https://www.nanoporetech.com

Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.